Transactions
33
Insider / Wave Life Sciences, Inc.
GLAXOSMITHKLINE PLC
Insider at Wave Life Sciences, Inc.
- Company
- Wave Life Sciences, Inc.
- First filing on record
- July 30, 2020
- Latest trade on record
- December 11, 2025
- SEC filings
- EDGAR ↗
GLAXOSMITHKLINE PLC, Insider at Wave Life Sciences, Inc., has disclosed 33 transactions in WVE, TBPH, CVRX and 5 more since July 30, 2020: 6 purchases (7 open-market buys) and 4 sales, worth about $563.6M at the reported prices. The latest was filed December 15, 2025, 4 days after the trade; 6 filings were late against the 2-business-day Form 4 deadline.
Open-market buys
7
Sales
4
Avg. disclosure lag
10.7d
Trading in charts
Trade timeline
When does this person trade, how big, and in which direction? Every trade in the last 12 months.
Bought (above the line)Sold (below the line)
In the last 12 months GLAXOSMITHKLINE PLC made 1 purchase worth $28M and no sales. Dot size is the dollar amount.
Portfolio mix
Which stocks does this person trade most? Tile size is dollars traded, all time on record.
GLAXOSMITHKLINE PLC has traded 6 stocks on record; the largest by dollars is INVA.
Reporting lag
Does this person report on time? One bar per filing against the Form 4 deadline.
On timeLate
3 of 10 filings on record were reported after the Form 4 deadline (two business days, counted here as 4 calendar days).
What kind of transactions
Most Form 4 rows are pay arriving or tax being withheld, not a decision to buy or sell. Only code P is an open-market purchase and code S an open-market sale. What each code means: Form 4 transaction codes.
| Code | Meaning | Rows | Shares | Value |
|---|---|---|---|---|
| C | Conversion of a derivative | 20 | 86,854,301 | — |
| P | Open-market purchase | 7 | 10,507,938 | $77.4M |
| S | Open-market sale | 4 | 32,010,004 | $392.2M |
| J | Other acquisition or disposal | 2 | 9,644,807 | $94.0M |
| Year | Rows | Bought | Sold |
|---|---|---|---|
| 2025 | 1 | 1 · $27.9M | 0 |
| 2024 | 1 | 1 · $22.3M | 0 |
| 2023 | 1 | 1 · $16.5M | 0 |
| 2022 | 2 | 0 | 0 |
| 2021 | 23 | 2 · $7.7M | 1 · $392.1M |
| 2020 | 5 | 1 · $2.8M | 3 · $92K |
Transactions
| Security | Side | Trade date | Disclosed | Lag | Shares | Price | Value | Flags | Source | Share |
|---|---|---|---|---|---|---|---|---|---|---|
| WVE | Buy P | December 11, 2025 | December 15, 2025 | 4d | 1,470,000 | $19 | $27.9M | indirect | Form 4 ↗ | |
| WVE | Buy P | September 27, 2024 | October 1, 2024 | 4d | 2,791,930 | $8 | $22.3M | indirect | Form 4 ↗ | |
| WVE | Buy P | December 7, 2023 | January 30, 2024 | 54d | 3,300,000 | $5 | $16.5M | lateindirect | Form 4 ↗ | |
| TBPH | Other J | September 16, 2022 | September 20, 2022 | 4d | — | — | — | indirectderivative | Form 4 ↗ | |
| TBPH | Other J | September 16, 2022 | September 20, 2022 | 4d | 9,644,807 | $10 | $94.0M | indirect | Form 4 ↗ | |
| CVRX | Exchange C | July 2, 2021 | July 6, 2021 | 4d | 10,055,408 | — | — | indirectderivative | Form 4 ↗ | |
| CVRX | Exchange C | July 2, 2021 | July 6, 2021 | 4d | 1,081,434 | — | — | indirectderivative | Form 4 ↗ | |
| CVRX | Exchange C | July 2, 2021 | July 6, 2021 | 4d | 331,399 | — | — | indirectderivative | Form 4 ↗ | |
| CVRX | Exchange C | July 2, 2021 | July 6, 2021 | 4d | 589,939 | — | — | indirectderivative | Form 4 ↗ | |
| CVRX | Exchange C | July 2, 2021 | July 6, 2021 | 4d | 513,312 | — | — | indirectderivative | Form 4 ↗ | |
| CVRX | Exchange C | July 2, 2021 | July 6, 2021 | 4d | 59,527 | — | — | indirectderivative | Form 4 ↗ | |
| CVRX | Buy P | July 2, 2021 | July 6, 2021 | 4d | 275,000 | $18 | $5.0M | indirect | Form 4 ↗ | |
| CVRX | Exchange C | July 2, 2021 | July 6, 2021 | 4d | 635,646 | — | — | indirect | Form 4 ↗ | |
| CVRX | Exchange C | July 2, 2021 | July 6, 2021 | 4d | 27,345 | — | — | indirect | Form 4 ↗ | |
| CVRX | Exchange C | July 2, 2021 | July 6, 2021 | 4d | 8,380 | — | — | indirect | Form 4 ↗ | |
| CVRX | Exchange C | July 2, 2021 | July 6, 2021 | 4d | 14,917 | — | — | indirect | Form 4 ↗ | |
| CVRX | Exchange C | July 2, 2021 | July 6, 2021 | 4d | 12,979 | — | — | indirect | Form 4 ↗ | |
| CVRX | Exchange C | July 2, 2021 | July 6, 2021 | 4d | 1,505 | — | — | indirect | Form 4 ↗ | |
| LYEL | Exchange C | June 21, 2021 | June 23, 2021 | 2d | 30,253,189 | — | — | indirectderivative | Form 4 ↗ | |
| LYEL | Exchange C | June 21, 2021 | June 23, 2021 | 2d | 30,253,189 | — | — | indirect | Form 4 ↗ | |
| INVA | Sell S | May 20, 2021 | May 24, 2021 | 4d | 32,005,260 | $12 | $392.1M | indirect | Form 4 ↗ | |
| DBTX | Exchange C | February 17, 2021 | February 19, 2021 | 2d | 1,737,619 | — | — | indirectderivative | Form 4 ↗ | |
| DBTX | Exchange C | February 17, 2021 | February 19, 2021 | 2d | 3,125,000 | — | — | indirectderivative | Form 4 ↗ | |
| DBTX | Exchange C | February 17, 2021 | February 19, 2021 | 2d | 7,119,850 | — | — | indirectderivative | Form 4 ↗ | |
| DBTX | Buy P | February 17, 2021 | February 19, 2021 | 2d | 150,000 | $18 | $2.7M | indirect | Form 4 ↗ | |
| DBTX | Exchange C | February 17, 2021 | February 19, 2021 | 2d | 327,852 | — | — | indirect | Form 4 ↗ | |
| DBTX | Exchange C | February 17, 2021 | February 19, 2021 | 2d | 247,324 | — | — | indirect | Form 4 ↗ | |
| DBTX | Exchange C | February 17, 2021 | February 19, 2021 | 2d | 458,487 | — | — | indirect | Form 4 ↗ | |
| BCYC | Sell S | July 15, 2020 | September 18, 2020 | 65d | 78 | $19 | $1,502 | lateindirect | Form 4 ↗ | |
| BCYC | Sell S | July 15, 2020 | September 18, 2020 | 65d | 3,069 | $19 | $60K | lateindirect | Form 4 ↗ | |
| BCYC | Sell S | July 14, 2020 | September 18, 2020 | 66d | 1,597 | $19 | $31K | lateindirect | Form 4 ↗ | |
| GNCA | Option / conversion P | July 24, 2020 | July 30, 2020 | 6d | 1,260,504 | $0 | $158K | lateindirectderivative | Form 4 ↗ | |
| GNCA | Buy P | July 24, 2020 | July 30, 2020 | 6d | 1,260,504 | $2 | $2.8M | lateindirect | Form 4 ↗ |
Filings
| Filed | Form | Accession | Rows | Status | Source |
|---|---|---|---|---|---|
| December 15, 2025 | Form 4 | 0001999371-25-020336 | 1 | published | EDGAR ↗ |
| October 1, 2024 | Form 4 | 0001999371-24-012789 | 1 | published | EDGAR ↗ |
| January 30, 2024 | Form 4 | 0001999371-24-001192 | 1 | published | EDGAR ↗ |
| September 20, 2022 | Form 4 | 0001387131-22-009897 | 2 | published | EDGAR ↗ |
| July 6, 2021 | Form 4 | 0001387131-21-007179 | 13 | published | EDGAR ↗ |
| June 23, 2021 | Form 4 | 0001387131-21-006822 | 2 | published | EDGAR ↗ |
| May 24, 2021 | Form 4 | 0001387131-21-006039 | 1 | published | EDGAR ↗ |
| February 19, 2021 | Form 4 | 0001387131-21-002710 | 7 | published | EDGAR ↗ |
| September 18, 2020 | Form 4 | 0001387131-20-008376 | 3 | published | EDGAR ↗ |
| July 30, 2020 | Form 4 | 0001387131-20-006914 | 2 | published | EDGAR ↗ |
Other insiders at Wave Life Sciences, Inc.
- Francis Chris See Remarks 36 rows
- Novartis Bioventures Ltd Insider 33 rows
- Moran Kyle Chief Financial Officer 19 rows
- Tan Aik Na Director 19 rows
- Thompson Travis Alvin Chief Financial Officer 14 rows
- Hannay Michael Charles Ferguson CHIEF PROD & SUPPLY CHAIN OFF 13 rows
- Skynner Michael CHIEF SCIENTIFIC OFFICER 13 rows
- HENRY CHRISTIAN O Director 12 rows
- Lee Kevin CHIEF EXECUTIVE OFFICER 12 rows
- Gutierrez-Ramos Jose-Carlos SVP, Chief Science Officer 10 rows
Everyone on file, with contracts and lobbying under the company's name: Wave Life Sciences, Inc..
Guides for this page
- What is SEC Form 4? Who files: officers, directors and owners of more than 10% of a class of the company's shares.
- Form 4 transaction codes P = purchase. S = sale. These are the two market trades.
- Insider buying vs insider selling Selling outweighs buying by a wide margin in normal times.
- Options and derivatives on Form 4 Table I = shares. Table II = options and other derivatives.
- What disclosure data cannot tell you Filings are late by design: up to 45 days for Congress, two business days for insiders.
Sources and method
| Source | Filings | Rows | First filed | Newest filed | Read the originals |
|---|---|---|---|---|---|
| SEC EDGAR, Form 4 | 10 | 33 | July 30, 2020 | December 15, 2025 | Form 4 list on EDGAR |
Site built October 22, 2026. Every row in the tables above links to its own filing. To quote a figure, use the Cite button at the top of the page; see how to cite and reuse.
Every row comes from the reporting owner's Form 4 as filed with the SEC (EDGAR ownership XML), read daily. "Value" is shares × the reported price; code P is an open-market purchase, S a sale, M an option exercise, A a grant. The lag is the filing date minus the trade date; Form 4 is due within two business days. Amendments (4/A) are not merged. Details on the methodology page; report an error on corrections.
Not investment advice. Figures are public disclosures shown as filed; they may lag the trade and may be amended later. No recommendation is made or implied.